

# **Global Veterinary Clinical Trials Market Size study, by Animal (Companion Animal, Livestock Animal, Other Animals), by Indication, Intervention, Sponsor and Regional Forecasts 2022-2032**

<https://marketpublishers.com/r/G40D0544630CEN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G40D0544630CEN

## **Abstracts**

Global Veterinary Clinical Trials Market is valued approximately at USD 4.94 billion in 2023 and is anticipated to grow with a remarkable CAGR of more than 9.00% over the forecast period 2024–2032. The veterinary clinical trials ecosystem is rapidly evolving as pharmaceutical innovation, animal health awareness, and precision-based veterinary research converge to drive evidence-based therapies for animal diseases. These trials are fundamental for validating the safety and efficacy of novel veterinary drugs, vaccines, and therapeutic approaches across both companion and production animals. Modern veterinary trials are embracing cutting-edge interventions such as monoclonal antibodies, gene therapies, and biosimilars—mirroring the sophistication traditionally seen in human healthcare. This scientific rigor, coupled with the growing recognition of animal health's role in global biosecurity, is significantly propelling market demand.

As the global veterinary industry matures, several structural and behavioral catalysts are fueling clinical trial activities. The steady increase in pet ownership, along with rising expenditure on pet health, has elevated the demand for targeted treatments and condition-specific medications, especially in companion animals. Simultaneously, zoonotic outbreaks and regulatory mandates for safer food chains have intensified the need for veterinary research in livestock and poultry populations. Governments and corporate sponsors are increasing their focus on clinical trials that reduce antimicrobial resistance and align with the One Health initiative. Meanwhile, the adoption of digital monitoring devices, wearable biosensors, and telehealth in trial protocols is streamlining data capture and enhancing compliance, thus improving trial efficiency and accuracy.

Despite promising opportunities, the veterinary clinical trials market faces several challenges. Complex trial designs, ethical considerations regarding animal testing, and limited availability of well-trained investigators are some of the core issues constraining progress. Moreover, differences in regulatory frameworks across countries can hinder multi-national trial deployment, delaying product approvals. However, partnerships between CROs, academic veterinary centers, and biopharma companies are bridging these gaps, leveraging global networks to standardize trial operations and increase throughput. The emergence of decentralized and virtual clinical trials in veterinary medicine is another transformative trend helping mitigate logistical and operational constraints.

Innovation in trial methodologies is reshaping the landscape. AI-driven predictive modeling, real-time remote monitoring, and cloud-based data analytics are being actively integrated to enhance trial designs, reduce timelines, and mitigate variability in endpoints. These advancements are enabling faster go-to-market strategies and more personalized treatment approaches for animals. Furthermore, strategic investments in disease-specific trials—especially for oncology, dermatology, and metabolic disorders in pets—are unlocking new avenues of commercial potential, creating a rich pipeline of veterinary pharmaceuticals awaiting regulatory nods.

Regionally, North America leads the global veterinary clinical trials market due to its advanced veterinary infrastructure, presence of major sponsors, and supportive regulatory pathways. Europe follows closely, benefiting from a well-organized veterinary services network and rising government funding for livestock research. Asia Pacific is expected to witness the highest growth rate over the forecast period, driven by growing livestock production, veterinary research funding, and increasing awareness about pet health in emerging economies like China, India, and Southeast Asia. Latin America and the Middle East & Africa are also gaining momentum, aided by international collaborations, improvements in veterinary education, and public-private partnerships focused on infectious disease control in animals.

Major market player included in this report are:

Zoetis Inc.

Boehringer Ingelheim International GmbH

IDEXX Laboratories, Inc.

Elanco Animal Health Inc.

Virbac

Covetrus, Inc.

Merck & Co., Inc.

VCA Animal Hospitals

Charles River Laboratories International, Inc.

VetDC, Inc.

Kindred Biosciences, Inc.

Jurox Pty Limited

Dechra Pharmaceuticals PLC

VetStem Biopharma, Inc.

Oncotect, Inc.

The detailed segments and sub-segment of the market are explained below:

By Animal

Companion Animal

Livestock Animal

Other Animals

By Indication

Oncology

Infectious Diseases

Dermatology

Others

By Intervention

Treatment

Prevention

Diagnostic

By Sponsor

Pharmaceutical Companies

CROs (Contract Research Organizations)

Academic & Research Institutions

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical Year – 2022

Base Year – 2023

Forecast Period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

## Contents

### **CHAPTER 1. GLOBAL VETERINARY CLINICAL TRIALS MARKET EXECUTIVE SUMMARY**

- 1.1. Global Veterinary Clinical Trials Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
  - 1.3.1. By Animal
  - 1.3.2. By Indication
  - 1.3.3. By Intervention
  - 1.3.4. By Sponsor
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

### **CHAPTER 2. GLOBAL VETERINARY CLINICAL TRIALS MARKET DEFINITION AND RESEARCH ASSUMPTIONS**

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
  - 2.3.1. Inclusion & Exclusion
  - 2.3.2. Limitations
  - 2.3.3. Supply Side Analysis
    - 2.3.3.1. Investigator Availability
    - 2.3.3.2. Clinical Infrastructure
    - 2.3.3.3. Regulatory Environment
    - 2.3.3.4. Trial Cost Structures
    - 2.3.3.5. Sponsor Capabilities
  - 2.3.4. Demand Side Analysis
    - 2.3.4.1. Animal Disease Burden
    - 2.3.4.2. Ethical & Welfare Considerations
    - 2.3.4.3. One Health Alignment
    - 2.3.4.4. Owner & Producer Awareness
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

## **CHAPTER 3. GLOBAL VETERINARY CLINICAL TRIALS MARKET DYNAMICS**

### **3.1. Market Drivers**

- 3.1.1. Rising Pet Ownership & Health Expenditure
- 3.1.2. Regulatory Push for Livestock Safety
- 3.1.3. Expansion of Biologic & Novel Therapeutics
- 3.1.4. Digitalization of Trial Monitoring

### **3.2. Market Challenges**

- 3.2.1. Complex Protocol Design & Execution
- 3.2.2. Ethical Concerns & Animal Welfare Regulations
- 3.2.3. Investigator & Site Shortages
- 3.2.4. Cross-Border Regulatory Divergence

### **3.3. Market Opportunities**

- 3.3.1. Decentralized & Virtual Trial Models
- 3.3.2. AI-Driven Predictive Analytics
- 3.3.3. Strategic CRO Partnerships
- 3.3.4. Disease-Specific Niche Trials

## **CHAPTER 4. GLOBAL VETERINARY CLINICAL TRIALS MARKET INDUSTRY ANALYSIS**

### **4.1. Porter's Five Forces Model**

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Model
- 4.1.7. Impact Analysis

### **4.2. PESTEL Analysis**

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

### **4.3. Top Investment Opportunities**

### **4.4. Top Winning Strategies**

### **4.5. Disruptive Trends**



- 4.6. Industry Expert Perspectives
- 4.7. Analyst Recommendation & Conclusion

## **CHAPTER 5. GLOBAL VETERINARY CLINICAL TRIALS MARKET SIZE & FORECASTS BY ANIMAL (2022–2032)**

- 5.1. Segment Dashboard
- 5.2. Companion Animal Trials Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.3. Livestock Animal Trials Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.4. Other Animal Trials Revenue Trend Analysis, 2022 & 2032 (USD Billion)

## **CHAPTER 6. GLOBAL VETERINARY CLINICAL TRIALS MARKET SIZE & FORECASTS BY INDICATION (2022–2032)**

- 6.1. Segment Dashboard
- 6.2. Oncology Indications Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.3. Infectious Disease Indications Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.4. Dermatology Indications Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.5. Other Indications Revenue Trend Analysis, 2022 & 2032 (USD Billion)

## **CHAPTER 7. GLOBAL VETERINARY CLINICAL TRIALS MARKET SIZE & FORECASTS BY INTERVENTION (2022–2032)**

- 7.1. Segment Dashboard
- 7.2. Treatment Interventions Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.3. Prevention Interventions Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.4. Diagnostic Interventions Revenue Trend Analysis, 2022 & 2032 (USD Billion)

## **CHAPTER 8. GLOBAL VETERINARY CLINICAL TRIALS MARKET SIZE & FORECASTS BY SPONSOR (2022–2032)**

- 8.1. Segment Dashboard
- 8.2. Pharmaceutical Company–Sponsored Trials Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.3. CRO-Sponsored Trials Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.4. Academic & Research Institution–Sponsored Trials Revenue Trend Analysis, 2022 & 2032 (USD Billion)

## **CHAPTER 9. GLOBAL VETERINARY CLINICAL TRIALS MARKET SIZE &**

## **FORECASTS BY REGION (2022–2032)**

### 9.1. North America

#### 9.1.1. U.S. Veterinary Clinical Trials Market

##### 9.1.1.1. By Segment Breakdown, 2022–2032

#### 9.1.2. Canada

### 9.2. Europe

#### 9.2.1. UK

#### 9.2.2. Germany

#### 9.2.3. France

#### 9.2.4. Spain

#### 9.2.5. Italy

#### 9.2.6. Rest of Europe

### 9.3. Asia Pacific

#### 9.3.1. China

#### 9.3.2. India

#### 9.3.3. Japan

#### 9.3.4. Australia

#### 9.3.5. South Korea

#### 9.3.6. Rest of Asia Pacific

### 9.4. Latin America

#### 9.4.1. Brazil

#### 9.4.2. Mexico

#### 9.4.3. Rest of Latin America

### 9.5. Middle East & Africa

#### 9.5.1. Saudi Arabia

#### 9.5.2. South Africa

#### 9.5.3. Rest of Middle East & Africa

## **CHAPTER 10. COMPETITIVE INTELLIGENCE**

### 10.1. Key Company SWOT Analysis

#### 10.1.1. Zoetis Inc.

#### 10.1.2. Boehringer Ingelheim International GmbH

#### 10.1.3. IDEXX Laboratories, Inc.

### 10.2. Top Market Strategies

### 10.3. Company Profiles

#### 10.3.1. Zoetis Inc.

##### 10.3.1.1. Key Information

- 10.3.1.2. Overview
- 10.3.1.3. Financial (Subject to Data Availability)
- 10.3.1.4. Product Summary
- 10.3.1.5. Market Strategies
- 10.3.2. Elanco Animal Health Inc.
- 10.3.3. Virbac
- 10.3.4. Covetrus, Inc.
- 10.3.5. Merck & Co., Inc.
- 10.3.6. VCA Animal Hospitals
- 10.3.7. Charles River Laboratories International, Inc.
- 10.3.8. VetDC, Inc.
- 10.3.9. Kindred Biosciences, Inc.
- 10.3.10. Jurox Pty Limited
- 10.3.11. Dechra Pharmaceuticals PLC
- 10.3.12. VetStem Biopharma, Inc.
- 10.3.13. Oncotect, Inc.

## **CHAPTER 11. RESEARCH PROCESS**

- 11.1. Research Methodology
  - 11.1.1. Data Mining
  - 11.1.2. Analysis
  - 11.1.3. Market Estimation
  - 11.1.4. Validation
  - 11.1.5. Publishing
- 11.2. Research Attributes

## I would like to order

Product name: Global Veterinary Clinical Trials Market Size study, by Animal (Companion Animal, Livestock Animal, Other Animals), by Indication, Intervention, Sponsor and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G40D0544630CEN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G40D0544630CEN.html>